Emergent BioSolutions Recognized by Security Magazine Among Best Security Organizations
Emergent BioSolutions (NYSE:EBS) was named recently to Security magazine's "Security 500: The Biggest and Best Security...
Emergent BioSolutions Ends Efforts to Acquire Protein Sciences
Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has ended all activities related to its planned acquisition of Protein Sciences Corporation...
Emergent BioSolutions Receives FDA Approval for BioThrax Supplemental Biologics License Application
Emergent BioSolutions Inc. (NYSE:EBS) announced today that the U.S. Food and Drug Administration (FDA) has approved Emergent's supplemental Biologics License Application (sBLA) for Anthrax Vaccine...
Emergent BioSolutions to Webcast Presentation at the J.P. Morgan 27th Annual Healthcare Conference on Wednesday, January 14, 2009
Emergent BioSolutions Inc. (NYSE: EBS) announced today that the company will be webcasting its presentation at the J.P. Morgan 27th Annual Healthcare Conference scheduled for Wednesday January 14,...
Emergent BioSolutions to Webcast Presentation at the 6th Annual Southwestern Showcase Investor Conference on November 20, 2008
Emergent BioSolutions Inc. (NYSE:EBS) announced today that the company will be webcasting its presentation at the 6th Annual Southwestern Showcase Investor Conference scheduled for Thursday, November...
Emergent BioSolutions Files Universal Shelf Registration Statement
Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has filed with the U.S. Securities and Exchange Commission (SEC) a universal shelf registration statement which, when declared effective,...
Emergent BioSolutions Reports Financial Results for Third Quarter and First Nine Months of 2008
Nov. 6, 2008--Emergent BioSolutions Inc. (NYSE:EBS) announced today its financial results for the third quarter and nine months ended September 30, 2008. Total revenues for the third quarter and nine...
Emergent BioSolutions to Webcast Presentation at the Rodman & Renshaw Annual Global Investment Conference on November 12, 2008
Oct. 31, 2008--Emergent BioSolutions Inc. (NYSE:EBS) announced today that the company will be webcasting its presentation at the Rodman & Renshaw Annual Global Investment Conference scheduled for...
Emergent BioSolutions to Release Third Quarter 2008 Financial Results and Conduct a Conference Call on November 6, 2008
Emergent BioSolutions Inc. (NYSE: EBS) announced today it will report financial results for the third quarter of 2008 on Thursday, November 6, 2008, after market close. Company management will host a...
U.S. Government Issues Declaration Covering Emergent BioSolutions’ BioThrax(R) and Anthrax Immune Globulin under Prep Act
October 9, 2008--Emergent BioSolutions Inc. (NYSE: EBS) announced today that two medical countermeasures included in its anthrax franchise -- BioThrax(R) (Anthrax Vaccine Adsorbed) and Anthrax Immune...
U.S. Government to Purchase Additional 14.5 Million Doses of BioThrax under New Contract Valued at up to $404 Million
Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has signed a new, multi-year, firm fixed price contract with the U.S. Department of Health and Human Services (HHS) to supply an...
Emergent BioSolutions Signs Contract with BARDA/NIAID, Valued at Up to $29.7 Million, to Fund Development of AV7909 – A Next Generation Anthrax Vaccine
Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has signed a contract with BARDA/NIAID, valued at up to $29.7 million, to fund the further development of AV7909, a next generation...